We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Rapid PCR POC Testing Platform Could Provide Affordable COVID-19 Surveillance, Screening and Diagnoses

By LabMedica International staff writers
Posted on 06 Apr 2021
A new rapid point-of-care and at home PCR diagnostic testing, screening and surveillance platform is being designed to perform COVID-19 testing at businesses, schools, homes, hotels, cruise ships, airports, airplanes and other locations.

The proprietary platform includes a countertop device being developed for Co-Diagnostics, Inc. More...
(Salt Lake City, UT, USA) by world experts in rapid PCR. The small cube-shaped device utilizes the company's Direct Saliva extraction-free protocol in connection with Logix Smart test reagents that are pre-packaged in saliva receptacle tubes. A person simply adds a swab or saliva sample to the receptacle tube and places the tube inside the device, which is then activated via a smartphone app and delivers rapid PCR COVID-19 results directly to the smartphone. The company believes that the convenience of displaying testing results on the smartphone empowers employees, students, travelers, and other individuals to quickly know their COVID-19 status, and may also provide a simple, straightforward way to satisfy requirements for entry into entertainment venues, clearance for airplane travel and hotel accommodations, work and school passports, and other applications.

The platform chemistry was created by Co-Diagnostics utilizing proprietary CoPrimer technology, Direct Saliva extraction-free protocols, and freeze-dried reagents. The device is being developed and engineered for Co-Diagnostics by internationally renowned experts in rapid PCR applications, and whose previous medical device inventions are in widespread use around the world.

With this platform, Co-Diagnostics plans to revolutionize the availability of accurate, fast and economical PCR tests as regular COVID-19 testing becomes part of the long-term protocol for many organizations. The rapid gold-standard PCR results from this testing platform would be differentiated from less accurate antigen tests. In addition, PCR may even detect the presence of genetic material of the SARS-CoV-2 virus being carried by vaccinated patients. The company agrees with epidemiologists that the rapid spread of the coronavirus and appearance of mutant strains mean that COVID-19 will remain with us for years, or even decades, leaving the world population to coexist with COVID-19 similar to other endemic diseases like flu, the common cold, and HIV.

The company expects that this planned elegant new platform will ultimately provide affordable COVID-19 PCR surveillance, screening and diagnoses to augment tests performed in high-complexity laboratory settings. While it is being designed for in-home use by responsible individuals, it is anticipated that businesses, physician's offices, dental offices, schools, theaters, sporting arenas, hotels, airlines and many other locations will avail themselves of the ease, accuracy and accessibility of this testing platform. The company expects that other tests will also become available on the device such as strep A, RSV, influenza A and influenza B, and potentially any other pathogen that can be sampled from a patient using saliva or a swab. It is expected that the new platform will be available for submission for regulatory approval later this year.

"The company has always envisioned ultimately developing a point-of-care/at-home diagnostic device making PCR accessible at affordable prices worldwide, and we are pleased that the culmination of years of development has resulted in a realization of this vision," said Co-Diagnostics CEO Dwight Egan. "Along with vaccines, social distancing with masks, and high-throughput laboratory testing, we believe that the wide-spread availability of this testing platform will truly give individuals the power to know their COVID-19 status so the world can get back to work, school, travel and vacations in a COVID-safe environment."

Related Links:
Co-Diagnostics, Inc.


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.